Infliximab and Biosimilar Market
Infliximab and Biosimilar Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Infliximab and Biosimilar Market Size and Growth
The Infliximab and biosimilars market is witnessing significant growth, driven by increasing demand for affordable treatment options for autoimmune diseases. The global market size is projected to reach approximately $10 billion by 2025. Competitive dynamics are influenced by patent expirations and the introduction of high-quality biosimilars, enhancing patient access to therapies.
Companies Covered
(Covid 19 Impact Covered)
◍ Janssen Biotech
◍ Merck and Co.
◍ Pfizer
The Infliximab and biosimilar market is competitive, with companies like Janssen Biotech, Merck & Co., and Pfizer driving growth through product innovation, strategic partnerships, and effective marketing. Their focus on affordable treatments boosts market access and patient options, enhancing revenue streams and expanding market share. Sales revenues:
- Janssen Biotech: $8 billion (2021)
- Merck & Co.: $48 billion (2021)
- Pfizer: $81 billion (2021)
Request Sample Report
